Literature DB >> 27279617

Changes in HIV-1 Capsid Stability Induced by Common Cytotoxic-T-Lymphocyte-Driven Viral Sequence Mutations.

P Schommers1,2,3, G Martrus1, U Matschl1, M Sirignano1, M Lütgehetmann4, L Richert1,5, T J Hope6, G Fätkenheuer2,3, M Altfeld7,8.   

Abstract

UNLABELLED: HIV-1-infected individuals with protective HLA class I alleles exhibit better control of viremia and slower disease progression. Virus control in these individuals has been associated with strong and potent HIV-1-specific cytotoxic-T-lymphocyte (CTL) responses restricted by protective HLA alleles, but control of viremia also occurs in the presence of selected CTL escape mutations. CTL escape mutations restricted by protective HLA class I molecules are frequently located in the conserved p24 Gag sequence of HIV-1 that encodes the conical capsid core and have been suggested to reduce viral replication capacity. In this study, the consequences of well-described CTL-associated p24 Gag sequence mutations for HIV-1 capsid stability were assessed using a cyclosporine (CsA) washout assay. The frequently occurring HLA-B57- and HLA-B27-associated CTL escape mutations T242N and R264K resulted in delayed capsid uncoating, suggesting modulation of capsid stability. The described compensatory mutations L268M and S173A observed in R264K viruses reconstituted the capsid-uncoating half-time. Interestingly, capsid stability was correlated with infectivity. Taken together, these data demonstrate that CTL-driven escape mutations within p24 Gag restricted by protective HLA class I alleles have a significant impact on capsid stability that might contribute to the persistent control of viral replication observed despite viral escape from CTL responses. IMPORTANCE: Sequence mutations within p24 Gag selected by CTL responses restricted by protective HLA class I alleles have been associated with reduced viral fitness. However, the precise mechanisms underlying the reduced viral replication capacity and lower viral loads associated with these mutations remain unclear. Here, we demonstrate that dominant HLA-B27-associated CTL escape mutations within HIV-1 capsid lead to enhanced capsid rigidity, providing a possible mechanism for the reduced viral fitness of these variants.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27279617      PMCID: PMC4984629          DOI: 10.1128/JVI.00867-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1.

Authors:  A Fassati; S P Goff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

Review 4.  Innate immune recognition of viral infection.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2006-02       Impact factor: 25.606

5.  Evolution and transmission of stable CTL escape mutations in HIV infection.

Authors:  P J Goulder; C Brander; Y Tang; C Tremblay; R A Colbert; M M Addo; E S Rosenberg; T Nguyen; R Allen; A Trocha; M Altfeld; S He; M Bunce; R Funkhouser; S I Pelton; S K Burchett; K McIntosh; B T Korber; B D Walker
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

6.  Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells.

Authors:  Amy E Hulme; Z Kelley; Eneniziaogochukwu A Okocha; Thomas J Hope
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

7.  The cyclosporin A washout assay to detect HIV-1 uncoating in infected cells.

Authors:  Amy E Hulme; Thomas J Hope
Journal:  Methods Mol Biol       Date:  2014

8.  The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells.

Authors:  Xavier Lahaye; Takeshi Satoh; Matteo Gentili; Silvia Cerboni; Cécile Conrad; Ilse Hurbain; Ahmed El Marjou; Christine Lacabaratz; Jean-Daniel Lelièvre; Nicolas Manel
Journal:  Immunity       Date:  2013-11-21       Impact factor: 31.745

9.  HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition.

Authors:  Toshiyuki Miura; Mark A Brockman; Arne Schneidewind; Michael Lobritz; Florencia Pereyra; Almas Rathod; Brian L Block; Zabrina L Brumme; Chanson J Brumme; Brett Baker; Alissa C Rothchild; Bin Li; Alicja Trocha; Emily Cutrell; Nicole Frahm; Christian Brander; Ildiko Toth; Eric J Arts; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-12-30       Impact factor: 5.103

10.  HIV-1 evades innate immune recognition through specific cofactor recruitment.

Authors:  Mahdad Noursadeghi; Greg J Towers; Jane Rasaiyaah; Choon Ping Tan; Adam J Fletcher; Amanda J Price; Caroline Blondeau; Laura Hilditch; David A Jacques; David L Selwood; Leo C James
Journal:  Nature       Date:  2013-11-06       Impact factor: 49.962

View more
  2 in total

1.  HIV-1 mutants that escape the cytotoxic T-lymphocytes are defective in viral DNA integration.

Authors:  Muthukumar Balasubramaniam; Benem-Orom Davids; Alex Bryer; Chaoyi Xu; Santosh Thapa; Jiong Shi; Christopher Aiken; Jui Pandhare; Juan R Perilla; Chandravanu Dash
Journal:  PNAS Nexus       Date:  2022-05-20

Review 2.  Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid.

Authors:  M T Boswell; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2019-03-21       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.